FDA approves icotrokinra, an oral interleukin-23 receptor antagonist, for adults and pediatric patients with moderate to ...
Pharmaceutical Technology on MSN
J&J wins FDA approval for Icotyde to enter psoriasis pill market
J&J’s Icotyde will take on AbbVie’s blockbuster injectable Skyrizi as analysts forecast a blockbuster future for the pill.
The company said the FDA approved Icotyde to treat moderate to severe plaque psoriasis in adults and pediatric patients 12 ...
Johnson & Johnson and Protagonist Therapeutics are countering the swarm of injectable biologics that have long dominated the ...
Johnson & Johnson won U.S. approval for a daily psoriasis pill that rivals the benefits of injectable medicines and could ...
Icotyde is the first targeted oral peptide IL‑23 receptor antagonist, designed to interrupt a core psoriasis inflammatory axis while avoiding injection-based administration typical of IL‑23 biologics.
The FDA today approved icotrokinra (Icotyde; Johnson & Johnson) for the treatment of adults and pediatric patients aged 12 ...
The FDA has approved the first oral interleukin (IL)-23-targeted therapy for plaque psoriasis, Johnson & Johnson announced.
"I was very ashamed. I felt like everywhere people were judging me," Amber Dean tells PEOPLE, recalling when her symptoms ...
In this video, Florence-Damilola Oyinola Odufalu, MD, a gastroenterologist and assistant professor of clinical medicine at the University of Southern California Keck School of Medicine, discusses the ...
In this video, Florence-Damilola Oyinola Odufalu, MD, a gastroenterologist and assistant professor of clinical medicine at the University of Southern California Keck School of Medicine, discusses the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results